Instead, glutaminase (GLS) inhibitors, including bis-2-(5-phenylacetamido-1,2,4- thiadiazol-2-yl) ethyl sulfide (BPTES) [157], CB-839, and compound 968, can alter the acetylation of histones H4 and H3 and downregulate the expression of many tumor-related genes in breast cancer [158]. The gene discussed is GLS; the disease is neoplasm.